CSIMarket Company Name, Ticker, Competitors, else..
 
Exagen Inc   (NASDAQ: XGN)
Other Ticker:  
 
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 
Price: $3.0000 $-0.12 -3.846%
Day's High: $3.24 Week Perf: -8.26 %
Day's Low: $ 2.92 30 Day Perf: -29.08 %
Volume (M): 240 52 Wk High: $ 6.22
Volume (M$): $ 720 52 Wk Avg: $2.48
Open: $3.12 52 Wk Low: $1.30



 Market Capitalization (Millions $) 55
 Shares Outstanding (Millions) 18
 Employees 200
 Revenues (TTM) (Millions $) 56
 Net Income (TTM) (Millions $) 7
 Cash Flow (TTM) (Millions $) -6
 Capital Exp. (TTM) (Millions $) 0

Exagen Inc
Exagen Inc is a biotechnology company that specializes in developing and commercializing diagnostic tests for autoimmune diseases. The company focuses on leveraging advanced testing technologies and genomics to provide personalized medicine solutions for patients with complex autoimmune conditions. Exagen's tests help physicians in accurately diagnosing and monitoring patients, allowing for targeted treatment plans and improved disease management. Some of the diseases that Exagen's tests detect and monitor include lupus, rheumatoid arthritis, and autoimmune-related kidney diseases. The company aims to enhance patient outcomes and contribute to the advancement of precision medicine in the field of autoimmune diseases.


   Company Address: 1261 Liberty Way Vista 92081 CA
   Company Phone Number: 560-1501   Stock Exchange / Ticker: NASDAQ XGN


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
DGX      % 
FCHS      % 
ISPC   -8.01%    
LH   -8.01%    
PMD   -16.82%    
MYGN   -7.44%    
• View Complete Report
   



Product Service News

Exagen Inc. Navigating the High Seas of Autoimmune Diagnostics Amidst Market Challenges

Published Thu, Nov 14 2024 9:30 PM UTC

In a significant development in the field of autoimmune disease diagnostics, Exagen Inc. recently announced the successful validation and regulatory submission for new biomarkers related to lupus and rheumatoid arthritis. This breakthrough comes through their innovative AVISE CTD platform, designed to enhance diagnostic clarity for clinicians treating patients plagued by the...
Exagen Inc

XGN Reports Remarkable 28.362% Revenue Growth in Q1 2024 Despite Financial Challenges

Exagen Inc has seen a significant increase in its share price over the past week, with a gain of 13.77%. This brings the share price to 0% during the second quarter of 2024. Despite this recent gain, Exagen Inc shares are still only trading 20.7% above its 52-week low.
The positive movement in Exagen Inc's share price can be attributed to its strong performance during the first quarter of 2024 earnings season. The company reported a decrease in loss per share, from $-0.44 a year ago to $-0.19 per share. Additionally, earnings per share improved from $-0.30 per share in the prior financial reporting period.
Exagen Inc

Evanescence of Deficit: XGN Struggles with Weakness in Fourth Quarter Financial Report

Exagen Inc (Nasdaq: XGN) has shown significant signs of weakness in its latest financial report for the fourth quarter of 2023. Despite a decrease in the loss per share compared to the previous year, the company still reported a loss of $-0.30 per share. This is only a slight improvement from the loss of $-0.83 per share in the same period a year prior.
Although there was a 7.229% increase in revenue to $13.77 million from $12.84 million in the corresponding reporting season, this is a relatively small growth rate and not enough to inspire confidence in the company's prospects. The sequential revenue growth of 2.601% from $13.42 million is also modest at best.
Exagen Inc

Exagen Inc. Reports Surprising $-0.31 Per Share Deficit Throughout Fiscal Year Ending September 30, 2023



Exagen Inc, a leading player in the Medical Laboratories sector, encountered a dip in revenue and suffered a greater financial shortfall in the fiscal period ending September 30, 2023. The company reported a loss of $-0.31 per share, while its revenue plummeted by -8.896% to $13.42 million compared to the same period in the previous year. In contrast, the Medical Laboratories sector as a whole recorded a revenue surge. These figures indicate a challenging business environment for Exagen Inc.
In the previous quarter, Exagen Inc generated a revenue of $14.14 million, with a bottom line of $-0.28 per share. However, in the fiscal period closing September 30, 2023, the company reported a net shortfall of $-5.415 million, a notable improvement from the deficit of $-8.096 million in the same quarter the prior year. Despite this improvement, Exagen Inc's financial performance remains cause for concern.
Exagen Inc

Exagen Inc Demonstrates Impressive Financial Growth and Improved Efficiency in Q1 2023

As a journalist, I have been studying the financial results of Exagen Inc and there are some very positive signs for the company in the first quarter of 2023. Firstly, the company?s ability to collect its outstanding accounts receivable from corporate clients has improved dramatically with a ratio of 5.34, which is above the company average. This indicates a healthy business climate in the Medical Laboratories industry and improving liquidity for customers during the first quarter of 2023.
Furthermore, the average receivable collection period for Exagen Inc in the March 31 2023 quarter has decreased to 68 days compared to 73 days in the Dec 31 2022 quarter. This indicates that the company is becoming more efficient and effective in its collections and suggests a solid level of financial discipline.






Exagen Inc's Segments
Commercial    54.2 % of total Revenue
Government    21.05 % of total Revenue
Client    23.83 % of total Revenue
Other    0.91 % of total Revenue





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com